Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Irbesartan/Amlodipine High FDC
NCT05688098Phase 1Completed
- Sponsor
- Handok
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of irbesartan and amlodipine in hypertension (HTN) (2 arms), sponsored by Handok. Primary endpoints: Area Under the Curve from time zero to last quantifiable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Sep 2022; status: completed.
02
Drugs
irbesartanamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05688098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05688098.